Back
GeneDx class action targets investors from April 2025 to May 2026

GeneDx class action targets investors from April 2025 to May 2026

Kessler Topaz said investors who bought GeneDx securities during the April 16, 2025 to May 4, 2026 class period have until August 3, 2026 to seek appointment as lead plaintiff.

Fact Check
Both the Robbins Geller GlobeNewswire press release and the firm's official case page confirm every element of the claim: Robbins Geller announced a GRAL securities class action, the class period runs May 13, 2025 to February 19, 2026, the lead plaintiff deadline is August 4, 2026, and the case is filed in the Northern District of California (Robbins v. Grail, Inc., No. 26-cv-05428, N.D. Cal.), which is a California federal court.
    Reference: 12
Summary

A securities fraud class action has been filed against GeneDx Holdings Corp. on behalf of investors who purchased or acquired WGS common stock between April 16, 2025 and May 4, 2026. Kessler Topaz Meltzer & Check, LLP said investors seeking to serve as lead plaintiff must file by August 3, 2026. The complaint centers on GeneDx’s acquisition of Fabric Genomics, announced on April 16, 2025 in a deal worth up to $51 million, including up to $33 million in cash upfront. It alleges GeneDx misrepresented or failed to disclose significant problems with Fabric’s viability while promoting the acquisition as a source of scalable, recurring revenue and broader market expansion. The suit says the alleged issues came into focus on May 4, 2026, when GeneDx reported first-quarter 2026 results showing an apparent drop in adjusted gross margin, lowered projected earnings, average reimbursement rates below expectations, and a $31.3 million impairment loss tied to Fabric. GeneDx shares fell more than 49% on that news. Kessler Topaz said investors can seek lead plaintiff status, retain other counsel, or remain absent class members without affecting any potential recovery.

Terms & Concepts
  • lead plaintiff: A representative investor who directs a securities class action on behalf of the broader proposed class.
  • impairment loss: A write-down recognizing that an asset is worth less than its carrying value on a company’s books.